MedTrace Logo

Comparison of MENOPUR Liquid and Powder in Women Undergoing Assisted Reproductive Technology (ART)

NCT04163458 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 405

Last updated 2023-11-07

Study results available
· View outcomes & findings →

Summary

Development of multiple follicles and pregnancy in ovulatory women undergoing controlled ovarian stimulation as part of an assisted reproductive technology (ART) cycle.

Conditions

Interventions

DRUG

MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL

Solution for injection in pre-filled pen, subcutaneous administration

DRUG

MENOPUR powder and solvent for solution for injection, 75 IU

Solution for injection in vials (powder and diluent), subcutaneous administration

OTHER

Placebo (for MENOPUR solution for injection in pre-filled pen)

Solution for injection in pre-filled pen, subcutaneous administration

OTHER

Placebo (for MENOPUR powder and solvent for solution for injection)

Solution for injection in vials (powder and diluent); subcutaneous administration

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Global Clinical Compliance · Ferring Pharmaceuticals

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
42 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-10-25
Primary Completion
2021-05-28
Completion
2021-07-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04163458 on ClinicalTrials.gov